Prognostic model for lung adenocarcinoma based on experimental drug-resistant cell lines and clinical patients
This model bridges <i>in vitro</i> resistance mechanisms with clinical immune landscapes, offering a tool to stratify patients for EGFR-TKIs, immunotherapies, or combinatorial strategies.
Authors
- Liqing Hu (ORCID: https://orcid.org/0000-0003-3592-488X)
- Tong Zhou (ORCID: https://orcid.org/0000-0002-4459-7553)
- Hui Zou (ORCID: https://orcid.org/0000-0001-5387-4930)
- Hang Fai Kwok (ORCID: https://orcid.org/0000-0002-6349-4517)
- Junnan Li (ORCID: https://orcid.org/0000-0002-7422-0765)
- Cheng Cao (ORCID: https://orcid.org/0000-0001-7981-6114)
- Jiasheng Zhang (ORCID: https://orcid.org/0000-0002-4637-5655)
- Xinyang Zhang (ORCID: https://orcid.org/0000-0002-7159-3697)
- Fengxian Liu
Institutions
- Hunan Normal University (CN)
- University of Macau (MO)
Publication Details
- Journal
- Frontiers in Molecular Biosciences
- Published
- 2025-11-21
- DOI
- https://doi.org/10.3389/fmolb.2025.1654426
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hunan Normal University
- Universidade de Macau
- Natural Science Foundation of Hunan Province
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
- Faculdade de Ciências da Saúde, Universidade de Macau